|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
1,430,000,000 |
Market
Cap: |
104.12(B) |
Last
Volume: |
6,180,847 |
Avg
Vol: |
8,454,629 |
52
Week Range: |
$48.64 - $74.1 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 297 |
Guru Rank Value : 4.1 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Boston Scientific develops, manufactures and markets medical devices. Co.'s Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. Co.'s Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
125,097 |
292,774 |
846,826 |
1,890,829 |
Total Sell Value |
$8,578,386 |
$18,202,620 |
$47,460,549 |
$93,238,165 |
Total People Sold |
7 |
8 |
10 |
13 |
Total Sell Transactions |
13 |
22 |
39 |
73 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pratt Timothy A. |
EVP, GC & Chief Admin Officer |
|
2012-02-24 |
4 |
D |
$6.25 |
$5,969 |
D/D |
(955) |
74,638 |
|
- |
|
Pratt Timothy A. |
EVP, GC & Chief Admin Officer |
|
2012-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,012 |
75,593 |
|
- |
|
Pierce David A |
SVP and President, Endoscopy |
|
2012-02-24 |
4 |
D |
$6.25 |
$6,050 |
D/D |
(968) |
8,415 |
|
- |
|
Pierce David A |
SVP and President, Endoscopy |
|
2012-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,012 |
9,383 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2012-02-23 |
4 |
D |
$5.90 |
$15,086 |
D/D |
(2,557) |
119,594 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2012-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,064 |
122,151 |
|
- |
|
Mario Ernest |
Director |
|
2012-02-23 |
4 |
B |
$5.91 |
$59,100 |
D/D |
10,000 |
447,304 |
2.39 |
- |
|
Mario Ernest |
Director |
|
2012-02-21 |
4 |
B |
$6.12 |
$122,400 |
D/D |
20,000 |
427,304 |
2.39 |
- |
|
Pedersen John B. |
Pres, Uro & Womens Health |
|
2012-02-16 |
4 |
D |
$5.97 |
$8,680 |
D/D |
(1,454) |
3,233 |
|
- |
|
Pedersen John B. |
Pres, Uro & Womens Health |
|
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,048 |
4,687 |
|
- |
|
Lance Jean Fitterer |
SVP & Chief Compliance Officer |
|
2012-02-16 |
4 |
D |
$5.97 |
$10,107 |
D/D |
(1,693) |
67,305 |
|
- |
|
Lance Jean Fitterer |
SVP & Chief Compliance Officer |
|
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,588 |
68,998 |
|
- |
|
Pucel Kenneth |
EVP, Global Ops & Technology |
|
2012-02-16 |
4 |
D |
$5.97 |
$14,167 |
D/D |
(2,373) |
98,121 |
|
- |
|
Pucel Kenneth |
EVP, Global Ops & Technology |
|
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,747 |
100,494 |
|
- |
|
Onuscheck John Michael |
SVP & President, EMEA |
|
2012-02-16 |
4 |
D |
$5.97 |
$12,782 |
D/D |
(2,141) |
50,897 |
|
- |
|
Onuscheck John Michael |
SVP & President, EMEA |
|
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,060 |
53,038 |
|
- |
|
Nanavaty Maulik |
SVP & Pres, Neuromodulation |
|
2012-02-16 |
4 |
D |
$5.97 |
$3,875 |
D/D |
(649) |
54,585 |
|
- |
|
Nanavaty Maulik |
SVP & Pres, Neuromodulation |
|
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,115 |
55,234 |
|
- |
|
Neumann Lawrence R |
SVP and Pres, Emerging Markets |
|
2012-02-16 |
4 |
D |
$5.97 |
$10,603 |
D/D |
(1,776) |
70,601 |
|
- |
|
Neumann Lawrence R |
SVP and Pres, Emerging Markets |
|
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,943 |
72,377 |
|
- |
|
Pierce David A |
SVP and President, Endoscopy |
|
2012-02-16 |
4 |
D |
$5.97 |
$10,979 |
D/D |
(1,839) |
6,371 |
|
- |
|
Pierce David A |
SVP and President, Endoscopy |
|
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,121 |
8,210 |
|
- |
|
Phalen Michael P. |
EVP & President, MedSurg |
|
2012-02-16 |
4 |
D |
$5.97 |
$10,125 |
D/D |
(1,696) |
49,081 |
|
- |
|
Phalen Michael P. |
EVP & President, MedSurg |
|
2012-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,723 |
50,777 |
|
- |
|
Burns Brian R |
EVP - Global Quality & Reg Aff |
|
2012-02-16 |
4 |
D |
$5.97 |
$14,292 |
D/D |
(2,394) |
71,703 |
|
- |
|
1831 Records found
|
|
Page 22 of 74 |
|
|